nyra health, a leading provider of an AI-based platform for neurological therapy, announces the successful completion of a Series A financing round totaling €20 million. The round is led by Armira Growth, a leading European growth investor with a strong network in the healthcare and technology sectors. Existing investors such as Wellington Partners, Crane Venture Partners, which now oversees MassMutual Ventures' investments, and EVER Pharma are participating again.
With the capital, the Vienna-based company will further expand its technology platform in the DACH region, accelerate its expansion in the US, and pursue its goal of establishing a new standard for data-driven neurorehabilitation.
From 100 clinics to 40 million insured persons: nyra health maps the entire patient journey in neurotherapy
Neurological diseases such as stroke, dementia, and traumatic brain injury cause €65 billion in costs annually in Germany alone—mainly because care often stops or significantly decreases in intensity after discharge from the hospital. The result is gaps in care for those affected and rising costs due to inadequate follow-up care and avoidable long-term consequences for health insurance companies and cost bearers.
nyra health closes this gap and enables continuous therapy from inpatient stay to long-term outpatient care.
The approach has been widely accepted: the AI-based platform myReha is now in use in over 100 neurological clinics, where it increases the available therapy density even during the patient's stay. Treatment does not end with discharge: nyra health is a recognized digital application that is part of the standard care provided by the German Pension Insurance, Europe's largest rehabilitation provider, and ensures structured follow-up treatment over several months.
In addition, myReha has been shown to significantly increase therapy time while delivering substantial cost savings: 28 statutory and private health insurance companies already automatically reimburse myReha. More than 40 million insured individuals now have access to structured, AI-based home therapy with real-time feedback, thereby reducing the burden on the cost-intensive healthcare system.
Adaptive therapy based on multimodal AI
The nyra health platform connects patients and clinical professionals in a shared digital infrastructure.
At its heart is the MDR Class IIa certified medical device myReha. Patients train speech, cognition, fine motor skills, and everyday abilities with AI-supported real-time feedback. Specially developed speech models analyze pathological speech at the level of pronunciation, word retrieval, syntax, and semantic structure. At the same time, reaction times, error profiles, and training dynamics are continuously evaluated.
Based on this data, the therapy automatically adapts to performance level, fatigue, and progress. The effectiveness of the myReha therapy solution has been clinically proven: In a randomized controlled study, the additional use of myReha showed significantly greater improvements in cognitive and language functions compared to standard therapy.
At the same time, nyra insights structures the control by specialists: therapists see language developments, therapy intensity, and progress curves in real time, adjust programs, and create documentation automatically. This is complemented by the AI-supported Content Studio, which dynamically generates personalized therapy content specifically for therapy practices based on individual performance data. This creates a continuous cycle of analysis, content adaptation, and training control.
International expansion and AI expansion
With Series A financing, nyra health is consistently continuing its growth course and is initially focusing on further market penetration. In the DACH region, additional clinic groups will be connected and existing reimbursement models in Germany, Austria, and Switzerland will be expanded in a targeted manner. At the same time, the company is preparing to enter the US market—together with an international pharmaceutical company with which a market launch in the United States is planned.
nyra health is also investing in the technological advancement of its platform. The focus is on expanding multimodal AI models for therapeutic interaction and diagnostics. These are being developed as part of a funded research project worth €4.2 million and scientifically validated in collaboration with leading US research universities.
Comments on the financing
Christian Figge, Managing Partner, Armira Growth: Neurological rehabilitation can be made significantly more effective through digital solutions, especially in the area of speech ability. nyra health is considered a true category creator with a proprietary AI-based solution that seamlessly connects the entire care chain—from inpatient therapy to outpatient aftercare to home use—for the first time. We were also particularly impressed by the strong clinical evidence and deep integration into the German standard of care, which already gives nyra health access to over 40 million insured individuals. On this basis, the company is ideally positioned to define the market for digital neurorehabilitation internationally as well.
Moritz Schöllauf, CEO and co-founder, nyra health: "From the outset, our goal was to make our services widely available to those affected. Everyone who needs therapy after a stroke or other neurological disease should have access to effective, individualized care—regardless of where they live or how well their own healthcare system is set up. With this round of financing, we are taking another step in this direction."
About nyra health
nyra health was founded by an interdisciplinary team of experts in the fields of neurology, machine learning, and regulatory affairs. Based in Vienna, the company is developing the world's most advanced AI platform for neurological rehabilitation. The platform includes the CE-certified therapy software myReha (MDR Class IIa) and the clinical management system nyra insights. It is currently used in over 100 rehabilitation clinics, in the digital rehabilitation aftercare program of the German Pension Insurance Fund, and by patients with the support of over 28 health insurance companies. nyra health is certified according to ISO 13485 and ISO 27001 and has published eleven scientific papers in leading clinical and technological journals. https://www.nyra.health/
About Armira
Armira is a leading European investment holding specialising in partnerships with entrepreneur-led and family-owned hidden champions with a long-term horizon. The firm manages more than EUR 5 billion in assets and is backed by a broad base of entrepreneurs, entrepreneurial families, and long-term oriented investors. Armira provides full-lifecycle capital, ranging from minority growth to majority positions. www.armira.de/en/
Press Contact:
E:prams(at)nyra.health / M: +49 157 36498781 (for nyra health)
E: james(at)jamesculverhousecommunications.com / M: +44 (0)7943 808 349 (for Armira)